{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:15:50Z","timestamp":1793531750568,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jvacx.2024.100497","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T20:30:41Z","timestamp":1716496241000},"page":"100497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Comirnaty-induced cardiopulmonary distress and other symptoms of complement-mediated pseudo-anaphylaxis in a hyperimmune pig model: Causal role of anti-PEG antibodies"],"prefix":"10.1016","volume":"19","author":[{"given":"B\u00e1lint Andr\u00e1s","family":"Barta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila Bal\u00e1zs","family":"Dobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Tibor Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Ber\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Facsk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-797X","authenticated-orcid":false,"given":"J\u00e1nos","family":"Szebeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2024.100497_b0005","article-title":"Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?","author":"Garvey","year":"2020","journal-title":"Br J Anesthesia"},{"key":"10.1016\/j.jvacx.2024.100497_b0010","article-title":"mRNA Vaccines to Prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","author":"Banerji","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jvacx.2024.100497_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and Anaphylactic Reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvacx.2024.100497_b0020","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/ajt.16517","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jvacx.2024.100497_b0025","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.16516","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14\u201323, 2020","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jvacx.2024.100497_b0030","doi-asserted-by":"crossref","unstructured":"Team CC-R, Food and Drug A. Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:125-129.","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"10.1016\/j.jvacx.2024.100497_b0035","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jvacx.2024.100497_b0040","article-title":"Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100497_b0045","article-title":"Pseudo-anaphylactic reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis post Pfizer BNT162b2 vaccination","volume":"9","author":"Lim","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100497_b0050","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/all.14958","article-title":"Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jvacx.2024.100497_b0055","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jvacx.2024.100497_b0060","article-title":"Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals","volume":"9","author":"Nittner-Marszalska","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100497_b0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.22255","article-title":"Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk","volume":"4","author":"Shavit","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvacx.2024.100497_b0070","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1080\/21645515.2021.1917236","article-title":"Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility","volume":"17","author":"Gringeri","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jvacx.2024.100497_b0075","doi-asserted-by":"crossref","unstructured":"Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, et al.. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021;147:2075-2082 e2.","DOI":"10.1016\/j.jaci.2021.04.002"},{"key":"10.1016\/j.jvacx.2024.100497_b0080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40259-022-00536-8","article-title":"Allergic reactions to COVID-19 vaccines: risk factors, frequency, mechanisms and management","volume":"36","author":"Luxi","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.jvacx.2024.100497_b0085","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.jaip.2022.07.012","article-title":"Reporting of allergic reactions during Pfizer-BioNTech BNTT162B2 vaccination in Israel","volume":"10","author":"Anis","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jvacx.2024.100497_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.715844","article-title":"Anaphylaxis to Pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy","volume":"2","author":"McSweeney","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.jvacx.2024.100497_b0095","doi-asserted-by":"crossref","unstructured":"Wolfson AR, Robinson LB, Li L, McMahon AE, Cogan AS, Fu X, et al. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J Allergy Clin Immunol Pract. 2021;9:3308-3320 e3.","DOI":"10.1016\/j.jaip.2021.06.010"},{"key":"10.1016\/j.jvacx.2024.100497_b0100","first-page":"337","article-title":"A new look at type I immediate hypersensitivity immune reactions","volume":"36","author":"Warren","year":"1976","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jvacx.2024.100497_b0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0095-4543(21)01014-9","article-title":"Allergy and pseudoallergy: an overview of basic mechanisms","volume":"14","author":"Smith","year":"1987","journal-title":"J Prim Care"},{"key":"10.1016\/j.jvacx.2024.100497_b0110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1034\/j.1398-9995.1999.00155.x","article-title":"Pseudoallergy or nonallergic hypersensitivity","volume":"54","author":"Zuberbier","year":"1999","journal-title":"J Allergy"},{"key":"10.1016\/j.jvacx.2024.100497_b0115","doi-asserted-by":"crossref","unstructured":"Patterson A, Kendall P, Monroy J, C. P, Ren Z, Maya Jerath M. Patients with pseudoallergic reactions following COVID-19 vaccination are able to tolerate subsequent dosing. JACI. 2022;149:DOI: 10.1016\/j.jaci.2021.12.57.","DOI":"10.1016\/j.jaci.2021.12.578"},{"key":"10.1016\/j.jvacx.2024.100497_b0120","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.99.17.2302","article-title":"Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody","volume":"99","author":"Szebeni","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jvacx.2024.100497_b0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol"},{"issue":"18","key":"10.1016\/j.jvacx.2024.100497_b0130","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"2020","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jvacx.2024.100497_b0135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jvacx.2024.100497_b0140","doi-asserted-by":"crossref","unstructured":"Dezsi L, Meszaros T, Kozma G, M HV, Olah CZ, Szabo M, et al.. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor. Geroscience. 2022;44:597-618.","DOI":"10.1007\/s11357-021-00495-y"},{"key":"10.1016\/j.jvacx.2024.100497_b0145","doi-asserted-by":"crossref","unstructured":"Chen E, Chen BM, Su YC, Chang YC, Cheng TL, Barenholz Y, et al. Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex. ACS Nano. 2020. https:\/\/dx.doi.org\/10.1021\/acsnano.9b07218.","DOI":"10.1021\/acsnano.9b07218"},{"key":"10.1016\/j.jvacx.2024.100497_b0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Estape Senti","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.jvacx.2024.100497_b0155","unstructured":"Vrieze Jd. Suspicions grow that nanoparticles in Pfizer\u2019s COVID-19 vaccine trigger rare allergic reactions. Science. 2020. https:\/\/www.sciencemag.org\/news\/2020\/12\/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions."},{"key":"10.1016\/j.jvacx.2024.100497_b0160","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","article-title":"Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence of immunogenicity of PEG","volume":"41","author":"Kozma","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100497_b0165","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene Glycol (PEG)-coated liposomes: roles of anti-PEG IgM and Complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jvacx.2024.100497_b0170","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nano.2011.06.003","article-title":"Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome","volume":"8","author":"Szebeni","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jvacx.2024.100497_b0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jconrel.2012.02.029","article-title":"Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model","volume":"160","author":"Szebeni","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.jvacx.2024.100497_b0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1515\/ejnm-2015-0011","article-title":"Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols","volume":"7","author":"Urbanics","year":"2015","journal-title":"Eur J Nanomedicine"},{"key":"10.1016\/j.jvacx.2024.100497_b0185","doi-asserted-by":"crossref","first-page":"63","DOI":"10.29016\/180427.1","article-title":"A porcine model of complement activation-related pseudoallergy to nano-pharmaceuticals: Pros and cons of translation to a preclinical safety test","volume":"1","author":"Szebeni","year":"2018","journal-title":"Prec Nanomed"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100497_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8040082","article-title":"Human clinical relevance of the porcine model of pseudoallergic infusion reactions","volume":"8","author":"Szebeni","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jvacx.2024.100497_b0195","unstructured":"Pfizer Pfizer. Responds to Research Claims 2023; Jan; 27: 2023. https:\/\/wwwpfizercom\/news\/announcements\/pfizer-responds-research-claims."},{"key":"10.1016\/j.jvacx.2024.100497_b0200","doi-asserted-by":"crossref","unstructured":"Klosko RC, Lynch SE, Cabral DL, Nagaraju K, Johnston YA, Steinberg JD et al. Death and disability reported with cases of vaccine anaphylaxis stratified by administration setting: an analysis of the vaccine adverse event reporting system from 2017 to 2022. Vaccines (Basel). 2023;11.","DOI":"10.3390\/vaccines11020276"},{"key":"10.1016\/j.jvacx.2024.100497_b0205","first-page":"3","article-title":"Cerebrovascular involvement in liposome-induced cardiopulmonary distress in pigs","volume":"15","author":"Bodo","year":"2005","journal-title":"J Liposome Res"},{"key":"10.1016\/j.jvacx.2024.100497_b0210","doi-asserted-by":"crossref","first-page":"H1050","DOI":"10.1152\/ajpheart.00622.2005","article-title":"Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function","volume":"290","author":"Szebeni","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jvacx.2024.100497_b0215","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.nano.2015.12.377","article-title":"Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model","volume":"12","author":"Jackman","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jvacx.2024.100497_b0220","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.2147\/IJN.S161369","article-title":"Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization","volume":"13","author":"Meszaros","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.jvacx.2024.100497_b0225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2019.07.005","article-title":"Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs","volume":"309","author":"Fulop","year":"2019","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100497_b0230","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.3390\/ijms25073595","article-title":"mRNA-LNP COVID-19 vaccine lipids induce complement activation and production of proinflammatory cytokines: Mechanisms, effects of complement inhibitors, and relevance to adverse reactions","volume":"25","author":"Bakos","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jvacx.2024.100497_b0235","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2147\/IJN.S187139","article-title":"Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice","volume":"14","author":"Orfi","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.jvacx.2024.100497_b0240","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.addr.2012.07.005","article-title":"A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines","volume":"64","author":"Szebeni","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jvacx.2024.100497_b0245","doi-asserted-by":"crossref","unstructured":"Szebeni J. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement? Drug Discov Today. 2018;23:487-492.49.","DOI":"10.1016\/j.drudis.2018.01.025"},{"key":"10.1016\/j.jvacx.2024.100497_b0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.jvacx.2024.100497_b0255","unstructured":"Pfizer Australia Pty Ltd. Nonclinical Evaluation Report: BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATYTM). https:\/\/www.tga.gov.au\/sites\/default\/files\/foi-2389-06.pdf 2021."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100497_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010059","article-title":"Biodistribution of RNA vaccines and of their products: evidence from human and animal studies","volume":"12","author":"Pateev","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jvacx.2024.100497_b0265","doi-asserted-by":"crossref","unstructured":"Szebeni, J. Evaluation of the Acute Anaphylactoid Reactogenicity of Nanoparticle-Containing Medicines and Vaccines Using the Porcine CARPA Model. In Characterization of Nanoparticles Intended for Drug Delivery, ttps:\/\/doi.org\/10.1007\/978-1-0716-3786-9_23,, Jeffrey D. Clogston et al. (eds.) Ed.; Methods in Molecular Biology, 2024. Ch 23, pp. 229-245.","DOI":"10.1007\/978-1-0716-3786-9_23"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T23:42:35Z","timestamp":1723506155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":53,"alternative-id":["S2590136224000706"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100497","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comirnaty-induced cardiopulmonary distress and other symptoms of complement-mediated pseudo-anaphylaxis in a hyperimmune pig model: Causal role of anti-PEG antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100497"}}